Trials / Completed
CompletedNCT01307488
Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 286 (actual)
- Sponsor
- Fundacion SEIMC-GESIDA · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A switch to a regimen consisting of ATV/RTV 300/100 mg QD + 3TC 300 mg QD in HIV-1 infected subjects in their first antiretroviral regimen and who are virologically suppressed on a regimen which consists of 2 NRTIs + any 3rd agent, is non-inferior to continue or switch to ATV/RTV 300/100 mg QD + 2 optimized NRTIs for maintenance of virological suppression.
Detailed description
Clinical Trial, phase IV, randomized, open label, multicenter with approved drugs in their use conditions. A switch to a regimen consisting of ATV/RTV 300/100 mg QD + 3TC 300 mg QD in HIV-1 infected subjects in their first antiretroviral regimen and who are virologically suppressed on a regimen which consists of 2 NRTIs + any 3rd agent, is non-inferior to continue or switch to ATV/RTV 300/100 mg QD + 2 optimized NRTIs for maintenance of virological suppression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ritonavir boosted Atazanavir + Lamivudine | ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day. |
| DRUG | Ritonavir boosted Atazanavir + 2 NRTIs | ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day. |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2014-04-01
- Completion
- 2015-03-01
- First posted
- 2011-03-03
- Last updated
- 2015-05-12
Locations
36 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01307488. Inclusion in this directory is not an endorsement.